Archive · 14 Nov 2025
Cohance Lifesciences Stock Plummets 28%, Impacting Mutual Funds by ₹1,500 Crore
Imagine a company's stock is like a toy that many people own pieces of, especially big groups called mutual funds.
Recently, this company's toy started breaking, losing a lot of its value, about 28% in just a few weeks.
This happened after its boss left and because the company didn't make as much money as expected.
The mutual funds, which had bought more pieces of the toy recently, lost a lot of money, over 1,500 crore rupees.
The company's profits also dropped by more than half.
They are hoping things will get better later, but for now, the toy is worth much less than it was at its highest point.
Cohance Lifesciences stock has fallen 28.40% over 12 consecutive trading sessions, reaching its lowest level since June 2024.
Domestic mutual funds collectively own a 16.49% stake in Cohance Lifesciences and have incurred an estimated loss of ₹1,545.7 crore due to the stock's decline.
The sharp drop in stock price was triggered by the resignation of the Managing Director and director, V. Prasada Raju, in late October.
Cohance Lifesciences reported a 52% year-on-year drop in net profit to ₹66.39 crore for the September quarter (Q2 FY26), with revenue also decreasing.
The company has trimmed its revenue guidance for FY26, expecting flattish growth, due to challenges including pharma destocking and biotech funding delays.
- Who
- Cohance Lifesciences, domestic mutual funds, and SBI Life Insurance
- What
- Cohance Lifesciences stock experienced a significant crash, leading to substantial losses for mutual funds holding its shares. The company also reported a sharp decline in its September quarter net profit and revised its revenue guidance.
- When
- The sell-off intensified in late October and continued through November, with the most recent data pertaining to the September quarter (Q2 FY26).
- Where
- India (stock market trading)
- Why
- The stock decline was triggered by the resignation of the company's Managing Director and director, compounded by weak quarterly financial performance, pharma destocking, biotech funding delays, and a temporary plant shutdown.
- Company
- Cohance Lifesciences
- Stock Price Decline (12 sessions)
- 28.40%
- Loss for Mutual Funds
- Approx. ₹1,545.7 crore
- Mutual Fund Stake (Q2)
- 16.49%
- Q2 FY26 Net Profit
- ₹66.39 crore (down 52% YoY)
- Q2 FY26 Revenue
- ₹555.57 crore (down from ₹603.77 crore YoY)
- Stock Discount to 1-year High
- 54%